|August 11, 2014|
|18:29 EDT||TRAK, SFM, HEAR, NUAN, CEMP, GSAT, GERN, MTZ, GALE, ICPT, DSTI, CALL, MM, SMG, HALO||On The Fly: After Hours Movers |
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
News For TRAK;DSTI;GSAT;HALO;ICPT;CEMP;SMG;GALE;NUAN;MM;MTZ;HEAR;CALL;GERN;SFM From The Last 14 Days
|November 16, 2015|
|13:38 EDT||NUAN||Nuance technical comments ahead of results|
The stock has been trading in a range since September of this year that is defined largely by a low at $16 and a high at $17.75. If the news is bullish, there could be a breakout above the top of the range. Next resistance levels above $17.75 are at $18.49, $18.96, which is the 52-week high, and $19.39. If the news is a negative surprise, there could be a break of the low of the range. Next supports below $16 would be at $15.21, $14.60, and $14.
|10:07 EDT||MTZ||MasTec management to meet with Jefferies|
Meetings to be held in Frankfurt/Vienna November 16-17 hosted by Jefferies.
|10:00 EDT||CEMP||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
|08:33 EDT||CEMP||Cempra upgraded to Overweight from Equal Weight at Morgan Stanley|
Subscribe for More Information
|06:19 EDT||CEMP||Cempra upgraded to Overweight from Equal Weight at Morgan Stanley|
|November 15, 2015|
|15:08 EDT||ICPT||Intercept reports analysis of Phase 3 obeticholic acid study, other data|
Intercept announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis, for presentation at the American Academy for the Study of Liver Diseases annual meeting. The studies evaluate investigational use of obeticholic acid, Intercept's lead farnesoid X receptor agonist. In a presentation titled, "Clinical Epidemiology of Primary Biliary Cirrhosis based on a Large U.S. Laboratory Database: Incidence and Trends in Serum Alkaline Phosphatase," an analysis of a clinical database of more than 575,000 patients who received an anti-mitochondrial antibody test showed that, of those patients, 6,107 were classified as having probable PBC based on a positive AMA test and ALP greater than the upper limit of normal at any time prior to AMA testing or up to one month following AMA testing. The study found that 69% of those likely PBC patients continued to have elevated ALP two years after the first positive AMA test. Meanwhile, a presentation titled "A Trial-Based Model of Liver Transplant and Liver-Related Death in Patients with Primary Biliary Cirrhosis" includes an analysis of data from the Phase 3 POISE trial of OCA in PBC using the UK-PBC predictive model of transplant-free survival based on ALP, bilirubin, alanine transaminase, albumin and platelet count. Risk was assessed at 5, 10 and 15 years based on a 12-month change from baseline in patients treated with OCA plus or minus ursodiol or placebo plus or minus ursodiol at the end of the POISE study. The UK-PBC risk algorithm showed a significantly lower risk of liver transplant or liver-related death in OCA-treated patients compared to placebo. Lastly, a presentation titled "Physician versus Patient Perceptions of Medical Care Quality in Primary Biliary Cirrhosis" showed that patients may not be properly informed about their ALP scores and the nature of PBC symptoms.
|14:38 EDT||ICPT||Intercept reports analyses of OCA in fatty liver patients|
Intercept Pharmaceuticals announced new results from the non-invasive evaluation of liver fibrosis in patients from the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH. In the trial, treatment with once daily 25 mg OCA was shown to reverse fibrosis in a "significant proportion" of biopsy-proven NASH patients, as observed by repeat liver biopsy at the end of the double-blind treatment phase at week 72, according to the company. Post-hoc analysis evaluated the early predictive value of three known non-invasive fibrosis tests -- FIB-4, APRI and NFS -- in identifying patients who experienced improvement in fibrosis. Each was assessed at baseline and over the course of treatment and then correlated with histologic changes observed in the OCA and placebo patients. The analysis demonstrated that OCA treatment of NASH patients led to a statistically significant decrease in FIB-4 from baseline as compared to placebo. Further, a decline in FIB-4 of 10% after 24 weeks of treatment predicted improvement in fibrosis by at least one stage as assessed by biopsy at 72 weeks, according to Intercept. Similarly, OCA-treated patients experienced a significant decrease in APRI as compared to placebo, and a 34% reduction in APRI at 24 weeks predicted improvement in fibrosis by at least one stage at 72 weeks. On average, OCA treatment reduced the FIB-4 score to less than 1.3 and the APRI score to less than 0.5, the respective cut-off values associated with advanced fibrosis, while placebo patients remained above these cut-offs. While NFS declined in the OCA-treated patients and increased in the placebo patients, it did not appear to be sensitive to changes in fibrosis, the company said.
|November 13, 2015|
|17:29 EDT||CALL||Man Group reports 5.26% passive stake in magicJack |
Subscribe for More Information
|15:35 EDT||ICPT||Intercept to host investor meeting|
Subscribe for More Information
|10:00 EDT||MTZ||On The Fly: Analyst Initiation Summary|
Today's noteworthy initiations include: AECOM (ACM) initiated with a Buy at Citi... Boston Properties (BXP) initiated with a Buy at BB&T... Brandywine Realty (BDN) initiated with a Buy at BB&T... CarMax (KMX) initiated with a Buy at Buckingham... Chicago Bridge & Iron (CBI) initiated with a Buy at Citi... First Data (FDC) initiated with a Neutral at Baird... Fluor (FLR) initiated with a Neutral at Citi... Glu Mobile (GLUU) initiated with a Buy at Roth Capital... Harman (HAR) initiated with an Outperform at William Blair... Highwoods Properties (HIW) initiated with a Hold at BB&T... Himax (HIMX) initiated with an Outperform at Baird... Jacobs Engineering (JEC) initiated with a Buy at Citi... KBR (KBR) initiated with a Sell at Citi... Kilroy Realty (KRC) initiated with a Buy at BB&T... MasTec (MTZ) initiated with a Neutral at Citi... McDermott (MDR) initiated with a Neutral at Citi... Momenta (MNTA) initiated with an Overweight at JPMorgan... National Retail Properties (NNN) initiated with a Hold at BB&T... Outerwall (OUTR) initiated with a Buy at Roth Capital... Quanta Services (PWR) initiated with a Neutral at Citi... SL Green Realty (SLG) initiated with a Buy at BB&T... SolarCity (SCTY) initiated with a Market Perform at Bernstein... Tobira Therapeutics (TBRA) initiated with an Outperform at Cowen.
|08:28 EDT||ICPT||American Association for Study of Liver Diseases to hold annual meeting|
The Liver Meeting 2015 is being held in San Francisco on November 13-17.
|07:19 EDT||MTZ||MasTec initiated with a Neutral at Citi|
Citi analyst Andrew Kaplowitz started MasTec with a Neutral rating and $21 price target.
|06:11 EDT||NUAN||Nuance volatility elevated into Q4 and outlook |
Nuance November call option implied volatility is at 67, December is at 40, January is at 37; compared to its 52-week range of 21 to 51, suggesting large near term price movement into the expected release of Q4 results on November 16.
|November 12, 2015|
|10:00 EDT||GALE||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: Angie's List (ANGI) upgraded to Market Perform from Underperform at Raymond James... CGI Group (GIB) upgraded to Buy from Hold at Societe Generale... Devon Energy (DVN) upgraded to Buy from Neutral at Guggenheim... EP Energy (EPE) upgraded to Neutral from Sell at Citi... Franco-Nevada (FNV) upgraded to Buy from Hold at Canaccord... Galena (GALE) upgraded on commercial business divestment at Oppenheimer... KPN (KKPNY) upgraded to Buy from Hold at HSBC... Macy's (M) upgraded to Buy from Neutral at Northcoast... Magic Software (MGIC) upgraded to Overweight from Equal Weight at Barclays... Range Resources (RRC) upgraded on valuation, 2016 outlook at RBC Capital... Raytheon (RTN) upgraded to Buy from Hold at Argus... Trend Micro (TMICY) upgraded to Buy from Neutral at Nomura.
|09:21 EDT||GALE||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Kohl's (KSS), up 5.4%... NetEase (NTES), up 6.3%... SunPower (SPWR), up 3.4%. ALSO HIGHER: Angie's List (ANGI), up 12.1% after after IAC (IAC) proposes to acquire the company... OHR Pharmaceutical (OHRP), up 7.4% after submitting a Special Protocol Assessment request to the FDA for OHR-102... Galena Biopharma (GALE) up 6.2% after being upgraded to Outperform from Perform at Oppenheimer... MannKind (MNKD), up 5.4% after confirming a planned stock sale. DOWN AFTER EARNINGS: Freshpet (FRPT), down 25%... Advance Auto Parts (AAP), down 11.1%... Viacom (VIAB), down marginally. ALSO LOWER: Derma Sciences (DSCI), down 30.4% after ending its Phase 3 clinical trials with aclerastide, DSC127, for diabetic foot ulcer healing... Sunedison (SUNE), down 11.2% after being downgraded to Sell from Neutral at Axiom.
|08:28 EDT||MTZ||MasTec re-initiated with a Buy at Craig-Hallum|
|07:19 EDT||GALE||Galena upgraded on commercial business divestment at Oppenheimer|
As noted earlier, Oppenheimer upgraded Galena to Outperform from Perform. The firm thinks the company's decision to divest its commercial business will help it unlock value by enabling it to focus exclusive on its cancer immunotherapy pipeline. Target $4.
|06:11 EDT||GALE||Galena upgraded to Outperform from Perform at Oppenheimer|
Subscribe for More Information
|November 11, 2015|
|16:26 EDT||ICPT||On The Fly: Top stock stories for Wednesday|
Stocks on Wall Street finished the day lower following a range-bound session marked by lighter than normal volume due to the Veteran's Day holiday. The lower participation allowed the market to digest the latest round of earnings with the reporting season beginning to wind down. Oil remained under pressure and closed near three week lows, as production has not really declined despite lower pricing. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet with no major data reported. U.S. bond markets were closed in observance of Veteran's Day. In China, industrial output rose 5.6% in October, matching March's reading as the weakest since 2008. Retail sales climbed 11% last month, beating expectations. COMPANY NEWS: Shares of Alibaba Group (BABA) trading in New York fell $1.62, or 1.98%, to $79.81 despite its report of blockbuster sales for the 11.11 shopping festival, better known as "Singles' Day." By the end of Wednesday in China, gross merchandise volume on Alibaba's platforms hit $14.3B, far exceeding last year's 24-hour total of $9.3B and topping the company's $11B forecast... Macy's (M) shares fell 14% to $40.41 after the department store operator cut its fiscal year sales and profit forecasts and said it would not follow an activist investor's suggestion to form a real estate investment trust. A number of its peers fell as well, including J.C. Penney (JCP), which dipped 1.9% despite previewing that its own quarterly results should be better than its prior expectations. Penney, which pre-announced stronger than expected same-store sales growth of 6.4% for Q3, is set to report full quarterly results on Friday morning... Anheuser-Busch InBev (BUD) and SABMiller (SBMRY) came to terms on a deal to combine the companies in a transaction worth $107B. In relation to their deal, Molson Coors (TAP) agreed to purchase SABMiller's 58% stake in MillerCoors, the joint venture formed in the United States in 2008, in a deal valued at $12B. Molson Coors was the biggest winner following today's announcements, rising 4.4% to $92.19. MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which rose 33c, or 4.39%, to $7.85 after Dialog Semiconductor (DLGNF) issued a statement saying it continues to "strongly" support its agreement to acquire the company. Also higher was Amazon (AMZN), which gained $14.18, or 2.15%, to $673.86 after research firm Morgan Stanley raised its price target on the name to $800 from $750 on the growing opportunity of Amazon Web Services. Separately, Wayfair (W) rallied 5.4% to $41.57 after Cowen analysts raised their target on the shares to $61 from $56 and reiterated an Outperform rating, calling Tuesday's selloff misguided. Among the noteworthy losers were Horizon Pharma (HZNP) and Insys (INSY), which declined a respective 19.6% and 8.7% after Express Scripts (ESRX) cut ties with Linden Care, a specialty pharmacy used by both companies. Also lower was PayPal (PYPL), which fell 67c, or 1.81%, to $36.33 shortly before the close after the Wall Street Journal reported that Apple (AAPL) is working on a mobile payments service that could compete with the firm's Venmo platform. Additionally, Intercept (ICPT) lost $24.02, or 11.66%, to $181.95 after FBR Capital cut its price target on the stock to $192 from $273, saying the market opportunity for Intercept's obeticholic acid liver disease candidate appears smaller than initially thought. INDEXES: The Dow dropped 55.99, or 0.32%, to 17,702.22, the Nasdaq slid 16.22, or 0.32%, to 5,067.02, and the S&P 500 declined 6.72, or 0.32%, to 2,075.00.
|09:29 EDT||ICPT||Intercept price target lowered to $192 from $273 at FBR Capital|
FBR Capital analyst Vernon Bernardino cut his price target for Intercept Pharmaceuticals to $192 and keeps a Market Perform rating on the name. The market opportunity of the company's investigational liver disease drug, obeticholic acid, is smaller than initially estimated, Bernardino admits in a research note. The analyst now believes OCA will achieve $2.2B in peak annual sales in non-alcoholic steatohepatitis, versus a prior estimate of $2.7B. His reduced forecast is based on the likelihood of Intercept having inadequate long-term safety data in NASH. Shares of Intercept closed yesterday at $205.97.